CA3125294A1 - Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design - Google Patents
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design Download PDFInfo
- Publication number
- CA3125294A1 CA3125294A1 CA3125294A CA3125294A CA3125294A1 CA 3125294 A1 CA3125294 A1 CA 3125294A1 CA 3125294 A CA3125294 A CA 3125294A CA 3125294 A CA3125294 A CA 3125294A CA 3125294 A1 CA3125294 A1 CA 3125294A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid sequence
- mammal
- raav particle
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795695P | 2019-01-23 | 2019-01-23 | |
| US62/795,695 | 2019-01-23 | ||
| PCT/US2020/014838 WO2020154535A1 (en) | 2019-01-23 | 2020-01-23 | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3125294A1 true CA3125294A1 (en) | 2020-07-30 |
Family
ID=71737005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3125294A Pending CA3125294A1 (en) | 2019-01-23 | 2020-01-23 | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12649004B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3914229A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7624727B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113347962B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020212026B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3125294A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020154535A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024223696A1 (en) * | 2023-04-24 | 2024-10-31 | Universiteit Gent | Compounds to treat inherited retinal disease |
| CN121046460A (zh) * | 2024-05-31 | 2025-12-02 | 上海朗昇生物科技有限公司 | 用于治疗Prom1相关视网膜疾病的新型治疗药物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0977880A2 (en) | 1997-04-21 | 2000-02-09 | University Of Florida | Materials and methods for treatment of retinal diseases |
| EP1463805B1 (en) | 2001-12-17 | 2014-10-22 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| WO2005003321A2 (en) | 2003-07-06 | 2005-01-13 | Roger Williams Medical Center | Methods of producing differentiated hematopoietic cells for treatment of cytopenia |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
| HUE041571T2 (hu) | 2010-04-23 | 2019-05-28 | Univ Florida | RAAV-guanilát-cikláz-készítmények és ejárások 1-es típusú Leber-féle veleszületett vakság (LCA1) kezelésére |
| US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
| AU2014216160B2 (en) | 2013-02-15 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | AAV8 retinoschisin expression vector for treating X-linked retinoschisis |
| JP2016517278A (ja) | 2013-03-15 | 2016-06-16 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法 |
| EP3113787B1 (en) | 2014-03-04 | 2019-12-04 | University of Florida Research Foundation, Inc. | Improved raav vectors and methods for transduction of photoreceptors and rpe cells |
| ES2822551T3 (es) | 2014-03-17 | 2021-05-04 | Adverum Biotechnologies Inc | Composiciones y métodos para la expresión génica mejorada en células de los conos |
| WO2015152941A1 (en) | 2014-04-04 | 2015-10-08 | Siemens Aktiengesellschaft | Combing multiple trending models for photovoltaic plant output forecasting |
| LT3137497T (lt) * | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| WO2016149664A1 (en) | 2015-03-18 | 2016-09-22 | University Of Florida Research Foundation, Inc. | Methods and compositions for restoration of cone function in bcm |
| WO2016183297A1 (en) | 2015-05-12 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone |
| WO2017070491A1 (en) | 2015-10-23 | 2017-04-27 | Applied Genetic Technologies Corporation | Ophthalmic formulations |
| US20170348387A1 (en) | 2016-02-29 | 2017-12-07 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for nphp5 lca-ciliopathy |
| JP6994018B2 (ja) | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| EP3585883A4 (en) | 2017-02-21 | 2021-04-14 | University of Florida Research Foundation, Incorporated | MODIFIED AAV CAPSID PROTEINS AND USES THEREOF |
| US20200270635A1 (en) | 2017-05-05 | 2020-08-27 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2019144077A1 (en) | 2018-01-22 | 2019-07-25 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods and compositions for treating genetically linked diseases of the eye |
| JP2022530845A (ja) | 2019-04-27 | 2022-07-04 | オクジェン アイエヌシー. | 眼疾患に対するadeno随伴ウイルス連ウイルスベクター媒介遺伝子治療 |
| JP7707081B2 (ja) | 2019-05-17 | 2025-07-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 網膜細胞を標的とした最適化された遺伝子治療 |
| WO2022011081A1 (en) | 2020-07-09 | 2022-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cell lines that produce human retinoschisin proteins and uses thereof |
| IL299927A (en) | 2020-07-29 | 2023-03-01 | Univ Florida | Improved adeno-associated virus-mediated therapies for X-linked retinoschisis |
| US12621783B2 (en) | 2020-07-31 | 2026-05-05 | Beijing Xiaomi Mobile Software Co., Ltd. | Method and apparatus for random access |
| WO2023081739A1 (en) | 2021-11-03 | 2023-05-11 | Teamedon International, Inc. | Methods of treating human x-linked retinoschisis using gene therapy |
| EP4511496A4 (en) | 2022-04-18 | 2026-06-24 | Abeona Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT OPTIC ATROPHY AND X-RELATED RETINOSCHISISIS |
| CN114848850B (zh) | 2022-04-28 | 2023-12-15 | 武汉中眸生物科技有限责任公司 | Rs1基因在制备xlrs治疗剂中的应用及治疗剂 |
-
2020
- 2020-01-23 WO PCT/US2020/014838 patent/WO2020154535A1/en not_active Ceased
- 2020-01-23 US US17/425,292 patent/US12649004B2/en active Active
- 2020-01-23 CA CA3125294A patent/CA3125294A1/en active Pending
- 2020-01-23 EP EP20744697.2A patent/EP3914229A4/en active Pending
- 2020-01-23 CN CN202080010452.1A patent/CN113347962B/zh active Active
- 2020-01-23 JP JP2021543230A patent/JP7624727B2/ja active Active
- 2020-01-23 AU AU2020212026A patent/AU2020212026B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3914229A1 (en) | 2021-12-01 |
| AU2020212026B2 (en) | 2025-10-09 |
| JP2022523050A (ja) | 2022-04-21 |
| AU2020212026A1 (en) | 2021-07-22 |
| CN113347962A (zh) | 2021-09-03 |
| JP7624727B2 (ja) | 2025-01-31 |
| WO2020154535A1 (en) | 2020-07-30 |
| US12649004B2 (en) | 2026-06-09 |
| US20220133909A1 (en) | 2022-05-05 |
| EP3914229A4 (en) | 2022-11-02 |
| CN113347962B (zh) | 2025-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230265455A1 (en) | Improved aav-mediated x-linked retinoschisis therapies | |
| US10308957B2 (en) | rAAV vectors and methods for transduction of photoreceptors and RPE cells | |
| EP4209501A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| US20170007720A1 (en) | Methods and compositions for gene delivery to on bipolar cells | |
| US20240067989A1 (en) | Compositions and Methods for Treating Retinal Disorders | |
| US20210188927A1 (en) | Compositions and methods for treating age-related macular degeneration | |
| ES2835032T3 (es) | Terapia génica para el tratamiento de una enfermedad de las células de cono retinianas | |
| US20260001917A1 (en) | Modified adeno-associated virus capsid proteins and methods thereof | |
| KR102839746B1 (ko) | 유전자의 망막 세포 내 발현을 위한 프로모터 및 이를 포함하는 벡터 시스템 | |
| US20220233655A1 (en) | Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme | |
| AU2020212026B2 (en) | Highly efficient transduction and lateral spread in the retina by a novel AAV virus enhanced by rational design | |
| US20230175015A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| CN112029773B (zh) | 编码bdnf的核酸及其应用 | |
| WO2026085386A1 (en) | Methods for treating xlrs | |
| JP2026503581A (ja) | 新規なカプシドタンパク質バリアント及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231229 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250117 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250117 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250117 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250227 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250627 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250708 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250728 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250728 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260116 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260116 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260526 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260527 |